Novel adjuvant strategy to potentiate bacitracin against MDR MRSA | Zendy

Jong-Chul Kim | Zendy; Byeonghwa Jeon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel adjuvant strategy to potentiate bacitracin against MDR MRSA

Author(s) -

Jong-Chul Kim,

Byeonghwa Jeon

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv463

Subject(s) - bacitracin , antimicrobial , microbiology and biotechnology , staphylococcus aureus , chemistry , antibiotics , biology , bacteria , genetics

Bacitracin is an antimicrobial peptide that is frequently used as an active ingredient in antimicrobial ointments. However, bacitracin resistance is highly prevalent in community-associated MRSA (CA-MRSA) strains and significantly compromises the effectiveness of existing antimicrobial ointments. In this study, we aimed to develop novel adjuvants to enhance the antimicrobial activity of bacitracin by using alkyl gallates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research